Preeclamptic toxemia: a disease ripe for proteomic discovery

Baker, Philip N.; Myers, Jenny

doi:10.1586/epr.09.5

Cited by 7 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In comparison, only one study has previously used conventional antibody microarrays to profile PE, but then targeting only LPE 73. Although conventional proteomic technologies have been applied 13, 14, 39–42, these efforts have revealed placenta tissue to be a difficult sample format to address 39, 42–44. By adopting optimized protocols for tissue extraction compatible with downstream antibody microarray analysis 64 (Dexlin‐Mellby et al ., submitted), we showed that our methodology could handle placenta tissue and generate detailed protein maps, taking the next step toward decoding the placenta proteome.…”

Section: Discussionmentioning

confidence: 99%

“…The etiology of PE is still largely unknown 10, 11, but PE is believed to be a two‐stage disease, where the first stage is characterized by an abnormal placentation and the second stage by a general vascular endothelial damage and inflammation induced by a yet unknown placental factor 2, 7, 12. Further studies delineating PE and revealing the underlying disease mechanisms at the molecular level are thus highly warranted 13, 14.…”

Section: Introductionmentioning

confidence: 99%

“…Deciphering the placental proteome, using various proteomic technologies 33–37 could shed further light on the disease and result in early diagnosing and therapeutic targeting of PE 14, 38. In fact, efforts to de‐convolute the molecular features of PE have been made using 2‐D gel electrophoresis or LC‐MS 13, 14, 39–42. However, targeting preeclamptic placenta, a heterogeneous tissue rich on lipids and glycogen, in a sensitive manner has proven difficult using conventional proteomic technologies 39, 42–44.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Tissue proteome profiling of preeclamptic placenta using recombinant antibody microarrays

Dexlin-Mellby

Sandström

Centlow

et al. 2010

Proteomics Clinical Apps

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tissue proteome profiling of preeclamptic placenta using recombinant antibody microarrays

Dexlin-Mellby

Sandström

Centlow

et al. 2010

Proteomics Clinical Apps

View full text Add to dashboard Cite

show abstract

“…Proteomics seems to be an ideal tool in studying PE. The main benefits of proteomics over conventional protein analysis methods are the possibility to analyze simultaneously thousands of proteins and the identification of novel proteins that may allow new hypothesis‐driven research to be conducted .…”

Section: Proteomics and Pementioning

confidence: 99%

Urine proteomic studies in preeclampsia

Kοlialexi¹,

Mavreli²,

Tounta³

et al. 2015

Proteomics Clinical Apps

View full text Add to dashboard Cite

Preeclampsia (PE) is a multisystem disorder of pregnancy that develops after 20 wk of gestation in previously normotensive women and complicates 5-8% of pregnancies. This rapidly progressive syndrome is usually diagnosed when the mother develops hypertension and proteinuria. The only effective treatment is delivery of the baby although early low-dose aspirin has been shown to significantly reduce the risk for PE. Recent advances in proteomic methods of protein separation, identification, and quantitation may allow for the identification of proteins and peptides that could facilitate early detection of disease, improve assessment of prognosis, and allow closer monitoring of women at risk for PE. This review summarizes all currently available markers for prediction and diagnosis of PE and presents urine proteomic studies performed for the identification of novel biomarkers.

show abstract

“…High dimensional biology techniques including genomics [66-69], transcriptomics [70-73], proteomics [74-85], metabolomics [86-90] and others -omic sciences are being utilized to gain insight into the pathophysiology of disease state and the identification of biomarkers in many disciplines including obstetrics [91-98]. …”

Section: Introductionmentioning

confidence: 99%

Differences and similarities in the transcriptional profile of peripheral whole blood in early and late-onset preeclampsia: insights into the molecular basis of the phenotype of preeclampsia^a

Chaiworapongsa¹,

Romero

Whitten³

et al. 2013

Journal of Perinatal Medicine

View full text Add to dashboard Cite

Objective Preeclampsia (PE) has been sub-divided into early- and late-onset phenotypes. The pathogenesis of these two phenotypes has not been elucidated. To gain insight into the mechanisms of disease, the transcriptional profiles of whole blood from women with early- and late-onset PE were examined. Methods A cross-sectional study was conducted to include women with: 1) early-onset PE (diagnosed prior to 34 weeks, n=25); 2) late-onset PE (after 34 weeks, n=47); and 3) uncomplicated pregnancy (n=61). Microarray analysis of mRNA expression in peripheral whole blood was undertaken using Affymetrix microarrays. Differential gene expression was evaluated using a moderated t-test (false discovery rate <0.1 and fold change >1.5), adjusting for maternal WBC count and gestational age. Validation by real-time qRT-PCR was performed in a larger sample size [early PE (n=31), late PE (n=72) and controls (n=99)] in all differentially expressed genes. Gene Ontology analysis and pathway analysis were performed. Results 1) 43 and 28 genes were differentially expressed in early- and late-onset PE compared to the control group respectively; 2) qRT-PCR confirmed the microarray results for early and late-onset PE in 77% (33/43) and 71% (20/28) of genes, respectively; 3) 20 genes that are involved in coagulation (SERPINI2), immune regulation (VSIG4, CD24), developmental process (H19) and inflammation (S100A10) were differentially expressed in early-onset PE alone. In contrast, only seven genes that encoded proteins involved in innate immunity (LTF, ELANE) and cell-to-cell recognition in the nervous system (CNTNAP3) were differentially expressed in late-onset PE alone. Thirteen genes that encode proteins involved in host defense (DEFA4, BPI, CTSG, LCN2), tight junctions in blood-brain barrier (EMP1) and liver regeneration (ECT2) were differentially expressed in both early- and late-onset PE. Conclusion Early- and late-onset PE are characterized by a common signature in the transcriptional profile of whole blood. A small set of genes were differentially regulated in early- and late-onset PE. Future studies of the biological function, expression timetable and protein expression of these genes may provide insight into the pathophysiology of PE.

show abstract

Preeclamptic toxemia: a disease ripe for proteomic discovery

Cited by 7 publications

References 32 publications

Tissue proteome profiling of preeclamptic placenta using recombinant antibody microarrays

Tissue proteome profiling of preeclamptic placenta using recombinant antibody microarrays

Urine proteomic studies in preeclampsia

Differences and similarities in the transcriptional profile of peripheral whole blood in early and late-onset preeclampsia: insights into the molecular basis of the phenotype of preeclampsia^a

Contact Info

Product

Resources

About

Preeclamptic toxemia: a disease ripe for proteomic discovery

Cited by 7 publications

References 32 publications

Tissue proteome profiling of preeclamptic placenta using recombinant antibody microarrays

Tissue proteome profiling of preeclamptic placenta using recombinant antibody microarrays

Urine proteomic studies in preeclampsia

Differences and similarities in the transcriptional profile of peripheral whole blood in early and late-onset preeclampsia: insights into the molecular basis of the phenotype of preeclampsiaa

Contact Info

Product

Resources

About

Differences and similarities in the transcriptional profile of peripheral whole blood in early and late-onset preeclampsia: insights into the molecular basis of the phenotype of preeclampsia^a